ABSTRACT
Structural variants (SVs), defined as any genomic rearrangements of 50 or more bp, are an important source of genetic diversity and have been linked to many diseases. However, their contribution to molecular traits in the brain and impact on neurodegenerative diseases remains unknown. Here, we report 170,996 SVs which were constructed using 1,760 short-read whole genomes from aging and Alzheimer’s disease subjects. We quantified the impact of cis-acting SVs on several molecular traits including histone modification, gene expression, mRNA splicing, and protein abundance in post-mortem brain tissues. More than 3,800 genes were associated with at least one molecular phenotype, and 712 (18%) with more than one phenotype, with a significant positive correlation in the direction of effect between RNA, histone peaks, and protein levels. SV associations with RNA and protein levels shared the same direction of effect in more than 87% of SV-gene pairs. We found reproducibility of SV-eQTLs across three groups of samples and multiple brain regions ranging from 81 to 98%, including the innate immune system related genes ERAP2 and GBP3. Additionally, associations of SVs with progressive supranuclear palsy, an amyloid-independent primary tauopathy, identified previously known and novel SVs at the 17q.21.31 MAPT locus and several other novel suggestive associations. Our study provides a comprehensive view of the mechanisms linking structural variation to gene regulation and provides a valuable resource for understanding the functional impact of SVs in the aged human brain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the US National Institutes of Health (NIH NIA U01 AG06888001, NIA R01-AG054005, NIA R56-AG055824, and NIA R01-AG054008)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board Protocol. Data used for this analysis comes from the AD Knowledge Portal (https://adknowledgeportal.synapse.org) and is hosted on the Sage Bionetworks Synapse platform for access by qualified investigators. Data was generated from post-mortem tissue and has been de-identified according to the Synapse terms of use, and is available through the submission of a AD Knowledge Portal Data Use Certificate (https://adknowledgeportal.synapse.org/DataAccess/DataUseCertificates). This platform is an Institutional Review Board (IRB) approved environment where data can be stored, accessed, and collaboratively analyzed. The Sage Bionetworks team facilitates data sharing and data integration activities within the AMP-AD Target Discovery Consortium and collaborative analyses between the academic and industry partners. The original study data was obtained from each subject and the Religious Orders Study and Rush Memory and Aging Project were approved by an Institutional Review Board (IRB) of Rush University Medical Center. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code Availability: All code used in this study has been provided in a single repository on GitHub (https://github.com/RajLabMSSM/AMP_AD_StructuralVariation). Data Availability: Data supporting the findings of this study are available from the AMP-AD Knowledge Portal (https://doi.org/10.7303/syn2580853). Specifically, whole-genome sequence data used for SV discovery are available for each cohort respectively: ROS/MAP (syn10901595); MSBB (syn10901600) and Mayo Clinic (syn10901601). ROS/MAP H3K9ac ChiP-seq data are available at syn4896408 and TMT proteomics data are available at syn17015098. RNA-seq reprocessed data from all cohorts were obtained from the RNAseq harmonization study (syn9702085). Splicing junction proportions were obtained from Raj et al. and a respective sQTL visualization (Shiny App) browser is available at https://rajlab.shinyapps.io/sQTLviz_ROSMAP/. ROSMAP data can also be requested at https://www.radc.rush.edu. All SV site-frequency data from 1,706 donors discovered separately in each cohort, complete nominal and permuted SV-xQTL summary statistics, and disease status association summary statistics are available at on GitHub (https://github.com/RajLabMSSM/AMP_AD_StructuralVariation).
